Scans

Tools

Home

Charts

Watchlist

Products

Pfizer Ltd

PFIZER

NSE

₹3,860.20+1.01%4 Nov 2026 at 12:47 PM

Reports

Pharma MNC Bulk Drugs

Pfizer Ltd

PFIZER

NSE

₹3,860.20

+1.01%

4 Nov 2026 at 12:47 PM

SOICxStockScans Reports

Ask AI

Pharma MNC Bulk Drugs

10 indices

Business Overview: What the company does, in plain English.Growth Catalysts: The forward growth drivers and triggers.Forensic Report: Accounting quality and red flags.Deep Dive Report: In-depth business analysis.

Pfizer Ltd is the Indian arm of one of the world’s largest biopharmaceutical companies, operating in the country since 1950 - the same year India adopted its Constitution. It began by manufacturing anti-tuberculosis drugs and pioneering large-scale antibiotic production, and over 75 years has built a portfolio of household names like Becosules and Corex alongside cutting-edge global medicines. The recurring approach is a deliberate pivot from legacy domestic brands toward innovative therapies from its parent’s pipeline, raising the share of global brands in its mix from 36.3% in 2016 to nearly half.

Business segments

One business - pharmaceuticals - organised into four therapeutic engines that share a common manufacturing backbone and a parent company’s pipeline, each attacking a different part of the patient journey: prevention, chronic care, hospital infection, and autoimmune disease.

1. Vaccines: the prevention franchise that leads India’s private market

A single pneumococcal vaccine, Prevenar 13, commands more than half the private market and anchors a business built on life-course vaccination - from infants to the elderly.

The flagship is a market leader - Prevenar 13 is India’s first and only pneumococcal conjugate vaccine approved for all age groups, from six-week-old infants to the elderly, and held a 46.2% unit share and 62.5% value share of the private pneumococcal vaccines market as of March 2023. It is the number-one vaccine by revenue in India’s private vaccine market.
A next-generation shot expands the adult franchise - Prevenar 20, a 20-valent vaccine for adults launched in August 2025, protects against 20 strains of the pneumonia-causing bacterium and captured 12.1% value share within months, ranking among India’s top two new pharmaceutical launches that year.
Demand is built through hospital partnerships, not just doctor prescriptions - the company sets up Centres of Excellence for adult vaccination inside corporate hospitals and runs the Duty@50 initiative, which has vaccinated over 190,000 adults by working with more than 20 corporates, two insurers, and 10-plus hospitals.
A digital funnel turns awareness into appointments - a 100% digital patient journey for Prevenar 13 reached 8 million people and drove engagement with 30,000 consumers, while a partnership with a leading e-pharmacy tapped a pool of 500,000 patients with co-morbid conditions to push vaccination fulfilment.

2. Internal Medicine: the chronic-care portfolio that reaches the mass market

A collection of legacy and global brands spanning cardiology, women’s health, vitamins, gastroenterology, pain, and neuroscience - increasingly distributed through partners rather than its own sales force.

The blood-thinner that beat generics - Eliquis, an oral anticoagulant, retained its position as the number-one novel oral anticoagulant in its represented market with a 35% share in FY25, even after losing patent protection in 2022 and facing more than 100 generic competitors. It achieved this by expanding its prescriber base by roughly 5,000 doctors and growing patient reach approximately threefold post-loss-of-exclusivity.
A 60-year-old vitamin brand still gaining share - Becosules, the number-one selling vitamin B-complex brand in India, contributes over 75% of the vitamins franchise sales and gained one percentage point of market share in a category worth about ₹3,000 Crore. It is now distributed through a technology-enabled partnership with GoApptiv rather than solely through Pfizer’s own field force.
Handing distribution to Cipla for wider reach - in December 2025, Pfizer signed a five-year deal giving Cipla the sole right to market, distribute, and sell four established brands - Corex Dx (the dry-cough market leader with a 15% value share), Corex LS, Dolonex, and Neksium - while Pfizer continues to manufacture them. The logic is to leverage Cipla’s broader network, especially in Tier-2 cities and beyond.
A new migraine drug opens a neuroscience front - Nurtec ODT, a first-of-its-kind orally disintegrating tablet for acute migraine, was launched targeting the CGRP pathway and is already onboarding over 500 new patients per month in its early growth phase. It avoids the blood-vessel constriction that makes older migraine drugs risky for patients with cardiovascular conditions.
Women’s health runs on trusted staples - the portfolio leads the folic-acid market with a 24% share and holds second place in combined oral contraceptives at 19%, anchored by Folvite (a top-five prescribed brand among gynaecologists) and Ovral L, the most prescribed oral contraceptive across specialties.

3. Hospitals Business Unit: the anti-infectives arsenal for critical care

A direct-to-hospital business selling advanced, often patented antibiotics that tackle drug-resistant infections - the kind of medicines where the alternative is often death.

The workhorse is a market leader in its niche - Zavicefta, a patented combination antibiotic for hospital-acquired pneumonia and complicated urinary and abdominal infections, is a market leader in its category and had already saved over 50,000 patients by FY22.
A new weapon against superbugs - Emblaveo, launched in October 2025, targets infections caused by metallo-β-lactamase-producing pathogens, a class of multidrug-resistant Gram-negative bacteria for which treatment options are severely limited.
Antibiotic stewardship is part of the product - the unit runs the KNOW AMR initiative to promote responsible antibiotic use, and its #PledgeWithPfizer campaign earned a Guinness World Record for the largest online video album of healthcare oaths, with over 11,000 participants. The ATLAS global surveillance programme monitors resistance patterns across 10 Indian hospital sites.

4. Inflammation & Immunology: the biologics bet on autoimmune disease

A small, specialist vertical selling high-science biologic and oral therapies to rheumatologists and dermatologists - built on a two-decade-old blockbuster and a newer, India-specific affordable alternative.

The anchor is a proven biologic - Enbrel, a TNF inhibitor for rheumatoid arthritis, psoriasis, and related conditions, has over 20 years of clinical use, more than 500 clinical trials behind it, and has treated over 6 million patients worldwide.
An India-specific oral option drives access - Betrecep, a JAK inhibitor launched in July 2023 as an affordability initiative, climbed to sixth rank in a market of over 85 brands within three years, supported by engagement with over 250 national Key Opinion Leaders.

Manufacturing and supply chain

One owned plant in Goa plus 18 contract manufacturers produce 6.8 billion pills and vials a year, with three-quarters of raw materials sourced locally.

The Goa plant is the in-house engine - established in 2002, it produces 186 million Standard Dosage Units (SDUs) annually across 25 SKUs and 18 products, and was the first site across Pfizer’s entire global supply network to achieve full IMEx certification, the company’s internal production-system standard.
Contract manufacturers handle the rest - 18 partner sites produce 1.94 billion units annually across 70 SKUs, including top brands like Becosules, Gelusil, and Corex DX.
Distribution reaches deep - 15 warehousing partners provide 3 lakh square feet of space and handle 35,000 to 38,000 transactions a month, feeding a network of over 7,500 stockists and 2,100 institutions.
The plant runs increasingly on sunlight - a 1,500 kWp solar installation at Goa generated roughly 2,580 MWh of clean energy in FY26, meeting about 49% of the site’s total energy needs, while the site maintains Zero Waste to Landfill and Zero Liquid Discharge status.

Group structure and partners

A subsidiary of Pfizer Inc. with no subsidiaries of its own, increasingly using commercial partnerships - not acquisitions - to expand reach for its established brands.

The ultimate holding company is Pfizer Inc., USA, with intermediate holding entities in the Netherlands, the US, and the UK. Pfizer Ltd itself has no subsidiaries, associates, or joint ventures.
The Becosules portfolio and other consumer-facing brands are managed through a technology-enabled distribution partnership with GoApptiv, a model designed to improve penetration without adding field-force headcount.
The company has been simplifying its asset base: it sold its Upjohn portfolio of six off-patent brands to Mylan in 2022 for ₹180.48 Crore, transferred its Thane manufacturing facility in 2023 for ₹178 Crore, and has received MIDC approval and will take steps to complete the sale of leasehold rights and buildings on its Turbhe land to Zoetis for ₹264.40 Crore.

Quick Ratios

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flow

Ratios

Peer Comparison

Quick Ratios

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flow

Ratios

Peer Comparison

Price

Charts

Documents

Edit Ratios

Mkt Cap

Market Capitalization

₹17,709Cr

Close Price

₹3,871.10

Industry

Pharma MNC Bulk Drugs

Price To Earnings

20.61

Price To Sales

6.67

Revenue

₹2,654Cr

Rev Gr TTM

Revenue Growth TTM

11.75%

PAT Gr TTM

PAT Growth TTM

2.39%

Consolidated

Standalone

Numbers

Percentage

Quarter	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Revenue RevenueCr	540	547	563	589	538	592	603	642	645	629	653	727
Growth YoY Revenue Growth YoY%	-13.2	-4.5	5.9	2.3	-0.4	8.3	7.1	9.1	19.9	6.3	8.3	13.2
Expenses ExpensesCr	387	357	385	399	392	364	393	412	417	393	406	466
Operating Profit Operating ProfitCr	153	189	177	189	146	228	210	230	228	236	248	261
OPM OPM%	28.3	34.6	31.5	32.1	27.1	38.4	34.8	35.8	35.4	37.5	37.9	35.9
Other Income Other IncomeCr	44	75	42	43	43	217	67	42	-20	50	45	179
Interest Expense Interest ExpenseCr	3	7	2	2	2	3	3	2	2	2	1	3
Depreciation DepreciationCr	18	14	15	15	15	16	14	14	14	15	14	14
PBT PBTCr	176	244	203	215	172	426	260	255	192	269	277	423
Tax TaxCr	46	65	52	57	45	95	68	66	50	69	72	110
PAT PATCr	130	179	151	158	128	331	192	189	142	200	204	313
Growth YoY PAT Growth YoY%	-13.7	38.0	61.1	6.3	-1.8	85.0	27.2	19.4	11.2	-39.6	6.6	65.7
NPM NPM%	24.1	32.7	26.8	26.9	23.7	55.9	31.8	29.4	22.0	31.8	31.3	43.1
EPS EPS₹	28.4	39.1	32.9	34.6	27.9	72.3	41.9	41.3	31.0	43.7	44.7	68.5

Quarter	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Revenue RevenueCr	540	547	563	589	538	592	603	642	645	629	653	727
Growth YoY Revenue Growth YoY%	-13.2	-4.5	5.9	2.3	-0.4	8.3	7.1	9.1	19.9	6.3	8.3	13.2
Expenses ExpensesCr	387	357	385	399	392	364	393	412	417	393	406	466
Operating Profit Operating ProfitCr	153	189	177	189	146	228	210	230	228	236	248	261
OPM OPM%	28.3	34.6	31.5	32.1	27.1	38.4	34.8	35.8	35.4	37.5	37.9	35.9
Other Income Other IncomeCr	44	75	42	43	43	217	67	42	-20	50	45	179
Interest Expense Interest ExpenseCr	3	7	2	2	2	3	3	2	2	2	1	3
Depreciation DepreciationCr	18	14	15	15	15	16	14	14	14	15	14	14
PBT PBTCr	176	244	203	215	172	426	260	255	192	269	277	423
Tax TaxCr	46	65	52	57	45	95	68	66	50	69	72	110
PAT PATCr	130	179	151	158	128	331	192	189	142	200	204	313
Growth YoY PAT Growth YoY%	-13.7	38.0	61.1	6.3	-1.8	85.0	27.2	19.4	11.2	-39.6	6.6	65.7
NPM NPM%	24.1	32.7	26.8	26.9	23.7	55.9	31.8	29.4	22.0	31.8	31.3	43.1
EPS EPS₹	28.4	39.1	32.9	34.6	27.9	72.3	41.9	41.3	31.0	43.7	44.7	68.5

Consolidated

Standalone

Numbers

Percentage

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Revenue RevenueCr	2,012	1,966	1,969	2,082	2,152	2,239	2,611	2,425	2,193	2,281	2,520	2,654
Growth Revenue Growth%	8.6	-2.3	0.1	5.7	3.4	4.0	16.6	-7.1	-9.6	4.0	10.4	11.8
Expenses ExpensesCr	1,580	1,617	1,468	1,516	1,579	1,526	1,775	1,616	1,558	1,541	1,616	1,681
Operating Profit Operating ProfitCr	432	349	500	565	573	712	836	809	635	740	904	973
OPM OPM%	21.5	17.8	25.4	27.1	26.6	31.8	32.0	33.4	29.0	32.5	35.9	36.6
Other Income Other IncomeCr	97	232	114	167	184	81	63	134	188	345	139	254
Interest Expense Interest ExpenseCr	1	1	0	1	11	15	10	13	15	8	9	9
Depreciation DepreciationCr	58	63	66	71	103	109	115	106	62	61	58	58
PBT PBTCr	470	517	548	660	642	669	773	824	746	1,016	976	1,160
Tax TaxCr	165	180	188	231	133	171	160	200	195	248	253	301
PAT PATCr	305	337	360	429	509	498	613	624	551	768	722	859
Growth PAT Growth%	203.9	10.4	6.9	19.2	18.7	-2.3	23.1	1.9	-11.6	39.2	-5.9	2.4
NPM NPM%	15.2	17.1	18.3	20.6	23.7	22.2	23.5	25.7	25.1	33.6	28.7	32.4
EPS EPS₹	66.7	73.6	78.7	93.8	111.3	108.8	133.9	128.5	120.5	167.8	157.9	187.8

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Revenue RevenueCr	2,012	1,966	1,969	2,082	2,152	2,239	2,611	2,425	2,193	2,281	2,520	2,654
Growth Revenue Growth%	8.6	-2.3	0.1	5.7	3.4	4.0	16.6	-7.1	-9.6	4.0	10.4	11.8
Expenses ExpensesCr	1,580	1,617	1,468	1,516	1,579	1,526	1,775	1,616	1,558	1,541	1,616	1,681
Operating Profit Operating ProfitCr	432	349	500	565	573	712	836	809	635	740	904	973
OPM OPM%	21.5	17.8	25.4	27.1	26.6	31.8	32.0	33.4	29.0	32.5	35.9	36.6
Other Income Other IncomeCr	97	232	114	167	184	81	63	134	188	345	139	254
Interest Expense Interest ExpenseCr	1	1	0	1	11	15	10	13	15	8	9	9
Depreciation DepreciationCr	58	63	66	71	103	109	115	106	62	61	58	58
PBT PBTCr	470	517	548	660	642	669	773	824	746	1,016	976	1,160
Tax TaxCr	165	180	188	231	133	171	160	200	195	248	253	301
PAT PATCr	305	337	360	429	509	498	613	624	551	768	722	859
Growth PAT Growth%	203.9	10.4	6.9	19.2	18.7	-2.3	23.1	1.9	-11.6	39.2	-5.9	2.4
NPM NPM%	15.2	17.1	18.3	20.6	23.7	22.2	23.5	25.7	25.1	33.6	28.7	32.4
EPS EPS₹	66.7	73.6	78.7	93.8	111.3	108.8	133.9	128.5	120.5	167.8	157.9	187.8

Consolidated

Standalone

Numbers

Percentage

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital Equity CapitalCr	46	46	46	46	46	46	46	46	46	46	46
Reserves ReservesCr	2,118	2,373	2,637	2,966	3,350	2,347	2,819	3,162	3,550	4,172	4,157
Current Liabilities Current LiabilitiesCr	658	787	954	892	873	774	853	657	547	570	627
Non Current Liabilities Non Current LiabilitiesCr	66	65	52	37	137	99	183	136	87	124	92
Total Liabilities Total LiabilitiesCr	2,888	3,271	3,690	3,940	4,405	3,266	3,901	4,001	4,229	4,911	4,922
Current Assets Current AssetsCr	1,632	2,079	2,417	2,715	3,048	1,925	2,396	2,525	2,738	3,513	3,803
Non Current Assets Non Current AssetsCr	1,256	1,192	1,273	1,225	1,357	1,341	1,504	1,476	1,491	1,398	1,119
Total Assets Total AssetsCr	2,888	3,271	3,690	3,940	4,405	3,266	3,901	4,001	4,229	4,911	4,922

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital Equity CapitalCr	46	46	46	46	46	46	46	46	46	46	46
Reserves ReservesCr	2,118	2,373	2,637	2,966	3,350	2,347	2,819	3,162	3,550	4,172	4,157
Current Liabilities Current LiabilitiesCr	658	787	954	892	873	774	853	657	547	570	627
Non Current Liabilities Non Current LiabilitiesCr	66	65	52	37	137	99	183	136	87	124	92
Total Liabilities Total LiabilitiesCr	2,888	3,271	3,690	3,940	4,405	3,266	3,901	4,001	4,229	4,911	4,922
Current Assets Current AssetsCr	1,632	2,079	2,417	2,715	3,048	1,925	2,396	2,525	2,738	3,513	3,803
Non Current Assets Non Current AssetsCr	1,256	1,192	1,273	1,225	1,357	1,341	1,504	1,476	1,491	1,398	1,119
Total Assets Total AssetsCr	2,888	3,271	3,690	3,940	4,405	3,266	3,901	4,001	4,229	4,911	4,922

Consolidated

Standalone

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow Operating Cash FlowCr	345	329	332	98	323	427	667	356	257	660	968
Investing Cash Flow Investing Cash FlowCr	-701	-250	-238	35	1,530	-469	-575	-36	54	-71	-562
Financing Cash Flow Financing Cash FlowCr	-62	-83	-110	-110	-164	-1,571	-181	-346	-235	-205	-798
Net Cash Flow Net Cash FlowCr	-417	-3	-17	23	1,690	-1,613	-88	-26	75	383	-392
Free Cash Flow Free Cash FlowCr	398	394	277	93	307	410	654	292	291	783	944
CFO To PAT CFO To PAT%	113.3	97.6	92.2	22.8	63.5	85.9	108.9	57.0	46.6	86.0	133.9
CFO To EBITDA CFO To EBITDA%	80.0	94.2	66.3	17.3	56.4	60.0	79.8	44.0	40.4	89.1	107.0

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow Operating Cash FlowCr	345	329	332	98	323	427	667	356	257	660	968
Investing Cash Flow Investing Cash FlowCr	-701	-250	-238	35	1,530	-469	-575	-36	54	-71	-562
Financing Cash Flow Financing Cash FlowCr	-62	-83	-110	-110	-164	-1,571	-181	-346	-235	-205	-798
Net Cash Flow Net Cash FlowCr	-417	-3	-17	23	1,690	-1,613	-88	-26	75	383	-392
Free Cash Flow Free Cash FlowCr	398	394	277	93	307	410	654	292	291	783	944
CFO To PAT CFO To PAT%	113.3	97.6	92.2	22.8	63.5	85.9	108.9	57.0	46.6	86.0	133.9
CFO To EBITDA CFO To EBITDA%	80.0	94.2	66.3	17.3	56.4	60.0	79.8	44.0	40.4	89.1	107.0

Consolidated

Standalone

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	Current
Valuation Ratios Valuation Ratios
Market Cap Market CapitalizationCr	8,173	8,658	9,997	15,191	18,412	20,684	19,906	15,847	19,184	18,317	21,592	17,709
Price To Earnings Price To Earnings	26.8	25.7	27.8	35.4	36.2	41.6	32.5	25.4	34.8	23.9	29.9	20.6
Price To Sales Price To Sales	4.1	4.4	5.1	7.3	8.6	9.2	7.6	6.5	8.8	8.0	8.6	6.7
Price To Book Price To Book	3.8	3.6	3.7	5.0	5.4	8.6	7.0	4.9	5.3	4.3	5.1	4.2
EV To EBITDA EV To EBITDA	16.6	20.4	16.4	23.5	28.3	27.5	21.9	17.3	27.0	21.1	20.5	14.0
Profitability Ratios Profitability Ratios
GPM GPM%	57.1	55.4	58.9	60.5	60.1	61.4	61.2	61.6	61.4	62.1	62.5	62.5
OPM OPM%	21.5	17.8	25.4	27.1	26.6	31.8	32.0	33.4	29.0	32.5	35.9	36.6
NPM NPM%	15.2	17.1	18.3	20.6	23.7	22.2	23.5	25.7	25.1	33.6	28.7	32.4
ROCE ROCE%	21.7	21.4	20.4	21.9	19.2	28.6	27.0	25.8	20.9	23.7	23.1	23.1
ROE ROE%	14.1	13.9	13.4	14.3	15.0	20.8	21.4	19.4	15.3	18.2	17.2	17.2
ROA ROA%	10.6	10.3	9.8	10.9	11.6	15.2	15.7	15.6	13.0	15.6	14.7	14.7
Operational Ratios Operational Ratios
Solvency Ratios Solvency Ratios
Liquidity Ratios Liquidity Ratios

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	Current
Valuation Ratios Valuation Ratios
Market Cap Market CapitalizationCr	8,173	8,658	9,997	15,191	18,412	20,684	19,906	15,847	19,184	18,317	21,592	17,709
Price To Earnings Price To Earnings	26.8	25.7	27.8	35.4	36.2	41.6	32.5	25.4	34.8	23.9	29.9	20.6
Price To Sales Price To Sales	4.1	4.4	5.1	7.3	8.6	9.2	7.6	6.5	8.8	8.0	8.6	6.7
Price To Book Price To Book	3.8	3.6	3.7	5.0	5.4	8.6	7.0	4.9	5.3	4.3	5.1	4.2
EV To EBITDA EV To EBITDA	16.6	20.4	16.4	23.5	28.3	27.5	21.9	17.3	27.0	21.1	20.5	14.0
Profitability Ratios Profitability Ratios
GPM GPM%	57.1	55.4	58.9	60.5	60.1	61.4	61.2	61.6	61.4	62.1	62.5	62.5
OPM OPM%	21.5	17.8	25.4	27.1	26.6	31.8	32.0	33.4	29.0	32.5	35.9	36.6
NPM NPM%	15.2	17.1	18.3	20.6	23.7	22.2	23.5	25.7	25.1	33.6	28.7	32.4
ROCE ROCE%	21.7	21.4	20.4	21.9	19.2	28.6	27.0	25.8	20.9	23.7	23.1	23.1
ROE ROE%	14.1	13.9	13.4	14.3	15.0	20.8	21.4	19.4	15.3	18.2	17.2	17.2
ROA ROA%	10.6	10.3	9.8	10.9	11.6	15.2	15.7	15.6	13.0	15.6	14.7	14.7
Operational Ratios Operational Ratios
Solvency Ratios Solvency Ratios
Liquidity Ratios Liquidity Ratios

Pharma MNC Bulk Drugs

	ABBOTINDIA	GLAXO	PFIZER	ASTRAZEN	PGHL	SANOFICONR	SANOFI
Market CapitalizationMkt CapCr	55,163	42,745	17,709	15,880	9,633	8,028	7,835
Close PriceClose₹	25,960.00	2,523.20	3,871.10	6,352.00	5,803.00	3,485.90	3,402.10
IndustryIndustry	Pharma MNC Bulk Drugs	Pharma MNC Bulk Drugs	Pharma MNC Bulk Drugs	Pharma MNC Bulk Drugs	Pharma MNC Bulk Drugs	Pharma MNC Bulk Drugs	Pharma MNC Bulk Drugs
Price To EarningsPE	34.16	37.79	20.61	93.62	25.36	28.70	21.50
Price To SalesPS	7.88	10.28	6.67	6.53	6.46	8.20	4.30
RevenueRevenueCr	7,004	4,159	2,654	2,432	1,491	979	1,822
Revenue Growth TTMRev Gr TTM%	6.3%	12.1%	11.8%	31.1%	16.1%	22.7%	-5.7%
PAT Growth TTMPAT Gr TTM%	11.2%	20.0%	2.4%	-7.5%	23.8%	28.4%	2.3%

	ABBOTINDIA	GLAXO	PFIZER	ASTRAZEN	PGHL	SANOFICONR	SANOFI
Market CapitalizationMkt CapCr	55,163	42,745	17,709	15,880	9,633	8,028	7,835
Close PriceClose₹	25,960.00	2,523.20	3,871.10	6,352.00	5,803.00	3,485.90	3,402.10
IndustryIndustry	Pharma MNC Bulk Drugs	Pharma MNC Bulk Drugs	Pharma MNC Bulk Drugs	Pharma MNC Bulk Drugs	Pharma MNC Bulk Drugs	Pharma MNC Bulk Drugs	Pharma MNC Bulk Drugs
Price To EarningsPE	34.16	37.79	20.61	93.62	25.36	28.70	21.50
Price To SalesPS	7.88	10.28	6.67	6.53	6.46	8.20	4.30
RevenueRevenueCr	7,004	4,159	2,654	2,432	1,491	979	1,822
Revenue Growth TTMRev Gr TTM%	6.3%	12.1%	11.8%	31.1%	16.1%	22.7%	-5.7%
PAT Growth TTMPAT Gr TTM%	11.2%	20.0%	2.4%	-7.5%	23.8%	28.4%	2.3%

FY2026

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2026

Sep 26